October 11, 2022 10:54 AM EDT

Rigel steps back from sNDA filing plans for bleeding disorder drug; NMD gives first look into myasthenia gravis program

Lei Lei Wu

News Reporter

In June, Rigel reported a Phase III fail for its only approved drug, fostamatinib, in warm autoimmune hemolytic anemia, or wAIHA for short, an autoimmune …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rigel steps back from sNDA filing plans for bleeding disorder drug; NMD gives first look into myasthenia gravis program

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Rigel steps back from sN­DA fil­ing plans for bleed­ing dis­or­der drug; NMD gives first look in­to myas­the­nia gravis pro­gram

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Rigel steps back from sNDA filing plans for bleeding disorder drug; NMD gives first look into myasthenia gravis program